Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441558 · ClinicalTrials.gov registry record · Phase 3
A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).
A Phase 3 study, sponsored by Sprout Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,723
- Enrollment target
NCT00441558 is a Phase 3 study that was terminated before completion, run by Sprout Pharmaceuticals. The registered enrollment target is 1,723 participants.
The verdict
NCT00441558, a Phase 3 study, was terminated before completion, sponsored by Sprout Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,723 participants
- Enrollment target
Study Summary
To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.
Interventions
- DRUG Flibanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,723 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00441558
The ClinicalTrials.gov registry entry for NCT00441558 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,723 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sprout Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Flibanserin is the first listed.
NCT00441558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00441558 about?
NCT00441558 is a clinical study titled "A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).". To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.
What is the current status of trial NCT00441558?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,723 participants. The study started on 2007-02. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00441558?
The interventions under investigation include: Flibanserin (DRUG).
Who is sponsoring clinical trial NCT00441558?
This trial is sponsored by Sprout Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.